ever you in call have Thomas. very to first welcome second after conference join us. pleased to Thank chosen call. and our is our And quarter IPO we year September This you last Y-mAbs are much earnings that
BLA and Since Thomas our as naxitamab advance our continue omburtamab IPO towards submission candidates we have product to the worked the hard that to make just lead sure through mentioned. clinic
months going the for naxitamab assets are the timeline November as the heard rolling start. before following you is We BLAs the year-end this initiate and omburtamab is for to both planning to of likely informs target be most and previously
compete to are count we we a grow. our quarter. head And Since commercialization of XX approval in that we IPO naxitamab innovate, believe we earlier and have track of omburtamab opportunities improve capitalize move we the by with our to to the have Y-mAbs And to the about presented feel April, record well since our growth then of started people year and positioned execution end on total and increased and We and the pipeline. demonstrated to ability a stage next by strong XXXX. that XX%
We GDXCDX this earlier to planning on IND year the to advanced expect are Lutetium-XXX. later That's antibody we in be our bispecific clinic the filing and filed this year. Omburtamab-DTPA antibody radiolabeled the
meeting FDA. all and high-risk for the XXX planning relapsed/refractory recruited have that need of had the the We we we patients neuroblastoma in for U.S. our with treatment the promising pre-BLA also Study the BLA
meeting the non-clinical naxitamab Accelerated The rolling alignment FDA the Company submission. portion portion BLA safety reached a November the to of and XXXX. an the with and in At the we on Approval along submit for expects clinical BLA Pathway with
will PPQ believes most February. likely portion, the For data to in the CMC portion from batches it in Company the the CMC complete sufficient have early XXXX
able waiting evaluation for application agency by that during raised Under the of by and the therapy be process ongoing Company matter to BLA, rolling the opportunity the basis, may rolling process, during on Company submission. The rather qualifies naxitamab’s the will will before all Company for discussions the for with the this it to of completed the provide sections individual with filing. be FDA a agency ever application the than enables the a address be and by breakthrough anticipates what to designation, which compound submitted reviewed modules rolling the be rolling
managed bone a antibody a naxitamab all patients presented. data from June, to refractory naked of on and marrow XX complete year's enrolled get this this XX ASCO with Conference in them neuroblastoma These primary also had Study alone. XX-XXX At in was patients response disease
scans. in after The their XX of XX%. XX patients addition, treatment the to other the corresponding by complete showed had neuroblastoma of in MIBG MIBG remission patients of and XX scans shown also In bone parts as
dramatic seeing responses patients. still very are we in So these nice
patients progression-free years. progression-free XX from of maintain after more months median survival the survival two than months XX two XX enrollment with months to
As still treatment. reminder an is naxitamab outpatient a
of the Phase Frontline recruitment naxitamab, neuroblastoma Phase double-refractory respond continues chemotherapy patients. MSK. high-risk also patients at has and in patients progress do is progressed addition, to not The respond In X It basically to is which Study and naxitamab study ongoing. for X anticipated not do as that
X.X antibody median of the a temozolomide we with combination age ASCO, relapses sargramostim, it's and and median call GM-CSF. data pre-treated the We of prior presented from the humanized to At patients the irinotecan, protocol presented. years, heavily HITS, the XX was
had patients prior XX% responses. after were split chemotherapy, in neuroblastoma assessed to relapses. documented two complete Early seven while of enrollment, refractory had responses response and was evenly patients partial cycles the and induction between At and high-risk XX
data in SIOP from is presented have Later be of planned data to while October. we in interim this naxitamab, at year, Phase France Lyon in expect the the treatment also to X the the osteosarcoma, in study
positive With well-positioned anti-GDX the range both antibody for believe, adult we of naxitamab, a including pediatric be develop cancers, GDX treatments and might we to indications.
The already been back also in IND. GDX Memorial has the vaccine In a Sloan addition, was and against patients Kettering. sponsored more vaccine MSK under New we update have treated with as originally date GDX a GDX, program May, developed XXX GDX development you at MSK with York cancer than vaccine announced seen, vaccine probably in on by proteins. To have our
of and with advances patients grade well a X Francisco at years. the And years in X XX% Conference XX Vaccine, progression-free a May, high-risk in two two Research a actually these tolerated patients. X Phase it's San saw with XX% for had also Stage we reported at no very XXXX, patients X particular, survival X vaccinated grade overall survival GDX-GDX toxicities. that data with we in presented In neuroblastoma the Neuroblastoma And Phase trial or
forward now year. of plan and cGMP using at we to vaccine, of Since scale we we in-licensed in manufactured we this to vaccine for product cGMP have route and the XXXX, manufacturing production the the begin in the clinic believe options the establish viable a newly June our commercial end explored have
towards clear and a approval forward GDX-GDX naxitamab high-risk path, path are prerequisite the believe a offer patients relapsed our for advancing development patient. for to a paradigm Vaccine and add-on treatment long-term now. vaccine been program for we the of may We the neuroblastoma as Establishment of move meaningful pediatric serving excited the program treatment to GDX-GDX in has improvement the natural
remission into we naxitamab put relapsing. them patients prevent vaccinate and first them So the to we then from in
Now omburtamab. onto turning
this BLA is Our second lead compound use radiolabeled later filing year. is a BX-HX Iodine-XXX. to that planned to with antibody have that Omburtamab also developed is monoclonal
developing metastasis neuroblastoma. initially leptomeningeal CNS We compound the for are for
the known The DSRCT, of with also BX-HX diffuse FDA small all neuroblastoma our filing of highly the DIPG and that XX tumors. before which are And known indication completed to are therapy first then rolling of needed as BLA intrinsic to be metastasis believe leptomeningeal under end. next patients CNS the for will desmoplastic our we breakthrough the for cell We target the the designation pontine tumors BLA. on the we portion also submit round positive glioma, year enrollment as as
four was study interim study, there The median data presented secondary Phase reversible of were being adverse XX related from is for the the at X.X in For escalation and X evaluated patients. them DIPG, positive ongoing age enrollment age treated kids recently of at least we endpoints. that X/X events or among in treatment. were dose were XX total to no limiting at X with of primary shared and no ASCO. A events the dose grade X grade four toxicities There events possibly grade years only and
survival from of And XX.X% DIPG are the overall first data cohort of XX the rate study. XX very the derived The we about of excited months all these at was XX patients.
historical of two XX diagnosis with are survival less As these in median following reminder, years. and for diagnosis nine patients than the a X% their XX% five children months only years for from to surviving
And MSK the XX% bispecific and testing escalation field bispecifics, escalation progressing dose survival enter our in are part of this of as dose the looking antibody already. this year we study planned. Phase GDX-GDX the X at the early median is clinical study at In study in
an next going. or the update year is expect on trial this the the of escalation of have depending dose continued how end We on beginning year, to towards
to during XXXX development the antibody CDXX-positive are CDXX, expect bispecific next clinical that of hematological the users we on our CDX be potential antibody working We for enter and to cancers. expect
approval We us voucher for which have one each products. priority upon received our pediatric review of designation, of rare omburtamab disease FDA to and naxitamab a entitle
drugs are to expire. approved program XXXX Assuming before X, the where currently the scheduled is October
Y-mAbs for of income of of license term generated The MSK XX% PRV. receive from And the get the XX% will will sale is XX.X% and therefore get PRV, MSK from entitled Y-mAbs they to provided, the the the remaining second, sales and our the XX%.
this, Bo? I to now financials. share invite his would quarter remarks Bo the with So second on
